January 17, 2025

Patient Care Declines After PE Acquisition

A recent study reveals that patient-reported care experience declined significantly at hospitals acquired by private equity firms, highlighting the potential impact of private equity acquisitions on patient care.

Conexiant

January 16, 2025

New XLH Guidelines Shift Primary Therapy to Burosumab

"Burosumab treatment normalized ALP serum levels in about 80% of both pediatric and adolescent cohorts, suggesting a substantial improvement of rickets in these patients," report authors of comprehensive new evidence-based recommendations for X-linked hypophosphatemia management.

Conexiant

January 15, 2025

Bertagnolli to Exit NIH Director Role

NIH director, Dr. Monica M. Bertagnolli, is stepping down after launching major initiatives in women's health and long COVID research, indicating optimism for their continuation under new leadership.

Conexiant

January 15, 2025

Hydrophobic, Chlorhexidine, vs. Standard PICCs

A randomized trial compares hydrophobic, chlorhexidine, and standard polyurethane peripherally inserted central catheters.

Conexiant

January 15, 2025

FDA Proposes Nicotine Limits for Tobacco

The US Food and Drug Administration has introduced a proposal to cap nicotine levels in cigarettes, with the goal of curbing addiction, reducing smoking rates, and averting millions of tobacco-related deaths by 2100.

Conexiant

January 13, 2025

Transcatheter Valve Replacement: Key 1-Year Outcomes

Transcatheter tricuspid-valve replacement reduced tricuspid regurgitation to a level that is mild or less in 95% of patients, with associated improvements in quality of life, functional capacity, and survival compared to medical therapy.

Conexiant

January 13, 2025

7-Day Antibiotic Course Matches 14 Days for Bloodstream Infections

7-day antibiotics noninferior to 14 days for bloodstream infections, reducing exposure and antibiotic-related risks.

Conexiant

January 13, 2025

Heart Age vs. CVD Risk in Care

Explore how heart age and short-term cardiovascular disease risk differ in guiding preventive care.

Conexiant

January 13, 2025

HF Event Reduction with Ertugliflozin: VERTIS CV

Ertugliflozin significantly reduces heart failure events in patients with type 2 diabetes and atherosclerotic cardiovascular disease.

Conexiant